
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
In partnership with Honeywell, Axendia research sheds light on opportunities and challenges experienced by leaders trying to modernize their life sciences production.





